Misplaced Pages

AVN-397 is a 5-hydroxytryptamine subtype 6 receptor antagonist drug developed by Avineuro Pharmaceuticals Inc. that can potentially be used to treat Alzheimer's disease and general anxiety disorder (GAD). Avineuro announced that it would start Phase II clinical trials in 2009, and those trials are ongoing as of 2012.

References

1. Griebel, Guy; Holmes, Andrew (2013). "50 years of hurdles and hope in anxiolytic drug discovery". Nature Reviews Drug Discovery. 12 (9): 667–687. doi:10.1038/nrd4075. ISSN 1474-1776. PMC 4176700. PMID 23989795. S2CID 6531810.
2. "AVN 397 - AdisInsight". adisinsight.springer.com. Retrieved 2023-03-12.
3. "Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-397, Potent Small Molecule For Treatment Of Anxiety And Alzheimer's Disease". BioSpace. Retrieved 2023-03-12.
4. Froestl, W.; Pfeifer, A.; Muhs, A. (2014). "Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014". Journal of Alzheimer's Disease. 42 (4): 1079–1149. doi:10.3233/JAD-141206. PMID 25061058. S2CID 998047. Retrieved 2023-03-12.
5. Medicines in Development / Mental Illnesses / 2012 Report (PDF), archived (PDF) from the original on 9 Jul 2022

This article about an anxiolytic is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antidementia agents
• Anxiolytics
• Psychoactive drug stubs